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Abstract
Background: Secondary hyperparathyroidism is a common feature in patients with chronic kidney
disease. Its serious clinical consequences include renal osteodystrophy, calcific uremic arteriolopathy, and
vascular calcifications that increase morbidity and mortality.
Reduced synthesis of active vitamin D contributes to secondary hyperparathyroidism. Therefore, this
condition is managed with activated vitamin D. However, hypercalcemia and hyperphosphatemia limit the
use of activated vitamin D.
In Denmark alfacalcidol is the primary choice of vitamin D analog.
A new vitamin D analog, paricalcitol, may be less prone to induce hypercalcemia and hyperphosphatemia.
However, a randomised controlled clinical study comparing alfacalcidol and paricalcitol has never been
performed.
The primary objective of this study is to compare alfacalcidol and paricalcitol. We evaluate the suppression
of the secondary hyperparathyroidism and the tendency towards hyperphosphatemia and hypercalcemia.
Methods/Design: This is an investigator-initiated cross-over study. Nine Danish haemodialysis units will
recruit 117 patients with end stage renal failure on maintenance haemodialysis therapy.
Patients are randomised into two treatment arms. After a wash out period of 6 weeks they receive
increasing doses of alfacalcidol or paricalcitol for a period of 16 weeks and after a further wash out period
of 6 weeks they receive the contrary treatment (paricalcitol or alfacalcidol) for 16 weeks.
Discussion: Hyperparathyroidism, hypercalcemia and hyperphosphatemia are associated with increased
cardiovascular mortality in patients with chronic kidney disease.
If there is any difference in the ability of these two vitamin D analogs to decrease the secondary
hyperparathyroidism without causing hypercalcemia and hyperphosphatemia, there may also be a
difference in the risk of cardiovascular mortality depending on which vitamin D analog that are used. This
has potential major importance for this group of patients.
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Background
Secondary hyperparathyroidism is a common complica-
tion of chronic kidney disease that is mainly caused by
decreased synthesis of 1,25(OH)2vitamin D and phos-
phate retention due to reduced kidney mass, and the
resultant hypocalcemia.
Treatment involves suppression of the parathyroid hor-
mone (PTH) production by restoration of
1,25(OH)2vitamin D levels by replacement therapy [1].
However, 1,25(OH)2vitamin D stimulates intestinal
phosphate and calcium absorption as well as phosphate
and calcium mobilisation from bone, leading to an
increased risk of hyperphosphatemia and hypercalcemia.
Hyperphosphatemia and hypercalcemia are major risk
factors for vascular calcification and coronary artery dis-
ease, the major cause of death in patients with chronic
kidney failure [2-4]. Therefore, a vitamin D analog that
suppresses the secondary hyperparathyroidism with low
calcemic and phosphatemic activity would be of interest.
The two vitamin D analogs available in Denmark are alfa-
calcidol (1α(OH)D3) and paricalcitol (19-norD2). Their
efficacy in suppressing hyperparathyroidism without
causing hyperphosphatemia and hypercalcemia has never
been compared.
A randomised, controlled study comparing paricalcitol
and calcitriol found that paricalcitol could control hyper-
parathyroidism with fewer sustained episodes of hyper-
calcemia and increased calcium × phosphate product than
calcitriol (1,25(OH)2D3) [5,6]. The lower calcemic and
phosphatemic activities of paricalcitol can be attributed to
decreased stimulation of bone resorption, and intestinal
calcium and phosphate absorption [7,8].
Alfacalcidol is converted to calcitriol by the liver enzyme
25 hydroxylase [9]. If alfacalcidol only has effects when
converted into calcitriol, we could apply the data from the
existing studies, and expect alfacalcidol to be more cal-
cemic and phosphatemic than paricalcitol.
However, a few studies intimate that alfacalcidol does not
need to be hydroxylated into calcitriol before exerting its
effects. Alfacalcidol apparently has its own intrinsic
effects. With similar doses of alfacalcidol and calcitriol
mediating the same degree of suppression of PTH, the
peak concentration of 1,25(OH)2D3 is markedly lower
after alfacalcidol administration than after calcitriol
administration [10]. Also the suppression of PTH secre-
tion from bovine thyroid glands in vivo, where the renal
25-hydroxylation of alfacalcidol is unavailable, is equal
between alfacalcidol and paricalcitol [11].
Previous studies are not able to guide the clinician in
choosing between alfacalcidol and paricalcitol when treat-
ing the patient with kidney disease and secondary hyper-
parathyroidism. Furthermore, paricalcitol is more
expensive than alfacalcidol and needs greater justification
if prescribed.
This is the first clinical study investigating whether there is
a difference between the ability of alfacalcidol and parical-
citol to suppress secondary hyperparathyroidism in
patients receiving chronic haemodialysis therapy without
causing hyperphosphatemia and hypercalcemia. This
study has been requested several times both in the litera-
ture and in the everyday clinical practice [12]. To address
this problem, we are currently recruiting for this non-com-
mercial investigator-initiated study.
Methods/design
Participants
Eligible subjects are > 18 years old and receiving chronic
haemodialysis therapy for at least 3 month prior to screen-
ing in any of nine Danish haemodialysis outpatient clin-
ics. After a period of minimum 6 weeks wash out, without
any kind of vitamin D supplement, and sufficiently regu-
lated p-phosphate (<1.8 mmol/l) and ionised p-calcium
(<1.25 mmol/l), the patients are candidates for inclusion
if p-iPTH is >350 pg/ml (37,1 pmol/l). The maximal
allowed dose of calcium-containing phosphate-binders is
1600 mg elementary calcium a day at the time of inclu-
sion. The patients may not be scheduled for parathyroid-
ectomy or planned to start treatment with calcimimetics
according to the local guidelines in the participating
departments. Anticonception and negative pregnancy test
should be present for fertile women. They are not admit-
ted to the study if any of the following criteria are present
(1) malignancy during the past five years (2) expected sur-
vival less than one year (3) pregnancy or breast feeding
(4) allergy to any ingredient of Etalpha® or Zemplar® (5) in
treatment with calcimimetics (6) participating in any
other clinical trials which could affect the endpoints.
Interventions
The study design is a crossover design where the patients
are randomised into two treatment arms (Figure 1). The
randomisation is performed after 6 weeks wash out dur-
ing which the patients are not allowed to receive any kind
of vitamin D supplement. The first arm receives alfacalci-
dol for 16 weeks and then goes through another 6 weeks
wash out period before they receive paricalcitol for 16
weeks. The second arm receive paricalcitol for 16 weeks
and then goes through another 6 weeks wash out period
before they receive alfacalcidol for 16 weeks. The drugs are
given at the end of haemodialysis treatment two or three
times a week depending on the frequency of haemodialy-
sis treatment. The start dose of alfacalcidol (Etalpha®Injec-
tion) is 3 μg a week and the start dose of paricalcitol
(Zemplar®Injection) is 9 μg a week. Every second week the
dose is titrated 50% according to p-phosphate, p-calciumBMC Nephrology 2009, 10:28 http://www.biomedcentral.com/1471-2369/10/28
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and p-iPTH. As long as p-phosphate <1.8 mmol/l and ion-
ised p-calcium <1.30 mmol/l and p-iPTH>150 pg/ml the
dose is increased. When p- iPTH ≤ 150 pg/ml and p-phos-
phate <1.8 mmol/l and ionised p-calcium <1.35 mmol/l
the dose is retained. If at any time p-phosphate >1.8
mmol/l or ionised p-calcium >1.35 mmol/l in two
repeated measurements the dose is reduced.
After inclusion the dose of calcium-containing phos-
phate-binders can only be unchanged or reduced. Ele-
vated p-phosphate should be treated thoroughly with
calcium-free phosphate-binders, dietary intervention and
re-evaluation of the dialysis dose. Elevated p-calcium
should lead to dietary intervention and reduction of cal-
cium containing phosphate binders. The calcium concen-
tration of dialysate is fixed to 1.25 mmol/l.
Objectives
In the current study we test the hypothesis, that there is a
difference between the ability of alfacalcidol and parical-
citol to suppress secondary hyperparathyroidism in
patients receiving chronic haemodialysis without causing
hyperphosphatemia and hypercalcemia.
Outcomes
The primary efficacy end point is the proportion of
patients achieving ≥ 30% reduction in iPTH from baseline
until the last 4 weeks of treatment with alfacalcidol or par-
icalcitol. The secondary outcomes is changes in ionised p-
calcium, p-phosphate, calcium × phosphate product, p-
alkaline phosphatase, p-25(OH)vitamin D, p-
1,25(OH)2vitamin D, blood pressure, pulse and pulse
pressure from baseline until the end of treatment with
alfacalcidol or paricalcitol respectively. The frequency of
parathyroidectomy or need for calcimimetics is registered.
Safety endpoints are b-haemoglobin, b-leukocytes, b-
trombocytes, p-sodium, p-potassium, p-magnesium, p-
bicarbonate, p-creatinine, p-urea, urea reduction rate, p-
albumin, p-alanine aminotransferase, p-bilirubin, p-C-
reactive protein and weight measured at the beginning
and after each treatment period.
All laboratory samples are drawn from the blood lines of
the dialyzer before start of the dialysis. P-iPTH, ionised p-
calcium and p-phosphate are measured every second
week during the treatment periods, the others parameters
are measured at the beginning and the end of each treat-
ment period. The urea reduction rate is calculated from a
urea measured before dialysis and a urea measured imme-
diately after dialysis. All laboratory analyses are per-
formed at the participating departments' local
laboratories.
Blood pressure and pulse are measured after 5 minutes
rest before dialysis, and weight is measured before the
dialysis session with clothes but no shoes.
Sample size
We assume that the proportion of patients achieving ≥
30% reduction in iPTH in the last four weeks of the treat-
ment period would be 50% in the alfacalcidol group and
68% in the paricalcitol group [13,14]. Based on 0.8 power
to detect a significant difference (P = 0.05, McNemars
test), 117 patients is required for inclusion.
Randomisation
A randomisation list is computer generated by an external
statistician. The patients are randomised in blocks of ten,
to secure equal distribution in the two groups in each
department. Assignments are enclosed in sequentially
numbered, opaque, sealed envelopes. When a patient is
included an envelope is opened sequentially and the
patient's initials and identification number written on the
assignment. The patients are enrolled and treatment
assignment ascertained by the primary investigator or any
of his/her delegated at each centre. The envelopes are gen-
erated by the coordinator and afterwards the allocation
list is packed in a sealed, opaque envelope and stored by
the coordinator.
Blinding
This is an open-label study.
Statistical methods
The frequency of reaching a 30% reduction in iPTH for a
minimum of 4 weeks is compared between the two treat-
ments in the same person by McNemar test for paired
observations. It is tested whether the effect is dependent of
the order of the periods.
Flow chart for comparative cross-over study of alfacalcidol  and paricalcitol Figure 1
Flow chart for comparative cross-over study of alfa-
calcidol and paricalcitol. After a 6 week wash out period, 
117 patients are included. Every participating patient receives 
16 weeks of treatment with alfacalcidol and 16 weeks of 
treatment with paricalcitol. The order of the treatments is 
decided by randomisation.
0  6  22  28  44  week  
alfacalcidol  paricalcitol 
paricalcitol  alfacalcidol 
Randomisation 
117 pt. 
Wash out 
(6 weeks)   
Treatment period 1 
(16 weeks) 
Treatment period 2 
(16 weeks) 
Wash out 
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Furthermore the effect of the two treatments after the first
period will be analysed separately from the second period.
The distribution of the variables and the changes in the
variables from the start until the end will be described.
Mean, median, standard deviation and range will be
reported.
All tests are two-sided tests α = 0.05. The changes during
the two treatments will be compared using tests for paired
observations.
Parametric tests (paired t-test) will be used if the distribu-
tions are normal and non-parametric test (McNemar test
and Wilcoxon signed ranks test) for ordered or continu-
ous data.
All participants that are evaluable will be included in the
statistical analysis.
The analysis will be performed in Statistica with the pro-
cedures: UNIVARIATA, FREQ and ANOVA.
The data analysis will be performed blinded. While doing
the statistical analysis the treatment groups will be
unknown.
All data will be described and the reason for missing val-
ues will be described. Every violation from the statistical
plan will be described in the final publication.
All eligible subjects receives a written description of the
study objective, schedule, benefits and risks, other treat-
ment possibilities, funding and contact information.
They are offered a consultation providing further informa-
tion. Here they can bring their relatives.
If the subject agrees to participate a written informed con-
sent is signed.
The study is in compliance with the Helsinki Declaration
and is approved by the Danish National Committee on
Biomedical Research Ethics (SJ-27), the Danish Medicines
Agency (EudraCT: 2006-005981-37) and Danish Data
Protection Agency (2007-41-0503)
Discussion
This article describes the protocol of a randomised trial
comparing the ability of alfacalcidol and paricalcitol to
suppress secondary hyperparathyroidism without causing
hypercalcemia and hyperphosphatemia in patients with
chronic kidney disease. As far as we know, alfacalcidol
and paricalcitol have never been compared in a ran-
domised clinical trial before.
The advantage of the cross-over design is an elimination
of the stochastic variation due to differences between indi-
viduals. This reduces the sample size needed. In Denmark
in year 2007, there was 2037 haemodialysis patients and
a death rate of 21.7% per year in this patient group [15].
Therefore, limiting the sample size is necessary.
When deciding the length of the treatment period it was a
balance between different considerations. First, it should
not be too long to avoid too many patients to drop out
before completing the study. With a mortality rate of
21.7% a year, this is a problem [15]. Second, the treat-
ment period should be long enough to reach a steady state
in parathyroid hormone suppression. Going through
other long term interventional studies with alfacalcidol or
paricalcitol, 16 weeks seems to be the minimal feasible
length [6,16]. Third, there is a risk of progression of the
secondary hyperparathyroidism over time. However, sec-
ondary hyperparathyroidism is a chronic disease. The dis-
ease should not progress in a period of 44 weeks, as long
as the patients are treated with some kind of active vita-
min D.
The wash out period should be long enough to avoid carry
over effect from one period to the other. However, a long
period with out vitamin D supplementation would be
ethically irresponsible, because of the important bone
preserving effects and the possible prophylactic effects
against cardiovascular disease. For clinical practice, it is
not possible to analyse plasma levels of either paricalcitol
or alfacalcidol. The pharmacokinetic data available are
therefore based on the decline in plasma 1,25(OH)2D3
following intravenous injection of the vitamin D analog.
The half-life of 1,25(OH)2D3 after intravenous adminis-
tration of alfacalcidol is 36 hours and paricalcitol 13-30
hours [10,17]. However, the suppression of parathyroid
hormone is much longer lasting with a maximal suppres-
sion 24 hours after intravenous alfacalcidol [18],
although not described for paricalcitol. Unfortunately,
there are not any studies describing the time until normal-
ised PTH. A wash out period 42 times the half-life of the
compounds and until maximal effect of the compounds,
must be sufficient.
A wash out period of 2-8 weeks is used in earlier studies
comparing vitamin D analogs with vitamin D analogs or
placebo [6,14,19]. The two therapies given during the first
treatment period will be compared, in order to analyze the
effect without any influence of an, if present, inadequate
wash out period,
The statistical analysis will be performed blinded. The par-
ticipating patients and study personal are not blinded to
the assignment, although it would be preferable. This is a
non-commercial investigator-initiated study and unfortu-BMC Nephrology 2009, 10:28 http://www.biomedcentral.com/1471-2369/10/28
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nately we did not have the resources to do so. However,
the endpoints are laboratory measurements, which are
objective parameters and therefore not prone to bias.
The randomisation list is kept by the study coordinator. In
a randomised study it would be ideal if an external person
had stored it. In this cross-over study where every patient
is receiving both drugs and only the order in which the
treatments are received is randomised, there is not the
same incentive to influence the randomisation for each
patient as there is in non cross-over studies. Furthermore,
the study coordinator is only involved in the randomisa-
tion in one of the participating centres.
The blood samples are analysed continually because of
the current dose titration. The analyses are performed at
each centre's local laboratory. As this is a cross-over study
it should not be a problem with different places analysing
the blood samples, since the patient is its own control and
we secure that each centre keeps the same analysis method
during the whole study.
Secondary hyperparathyroidism is suppressed by vitamin
D analogs in patients with chronic kidney disease, and
thereby is bone health preserved. Sufficient suppression of
hyperparathyroidism avoids the need of parathyroidec-
tomy (surgical removal of the parathyroid glands) in this
frail population. The main adverse effects are increasing
ionised p-calcium and increasing p-phosphate with
increasing doses of vitamin D analog. This is problematic,
because high ionised p-calcium and p-phosphate are asso-
ciated with increased risk of cardiovascular disease [20].
This study compares alfacalcidol and paricalcitol to deter-
mine if there is any difference in their ability to suppress
the secondary hyperparathyroidism in doses not raising
ionised p-calcium and p-phosphate. The results of this
study will be important to the every-day clinical practice
when treating secondary hyperparathyroidism in patients
with chronic kidney disease.
Abbreviations
iPTH: intact Parathyroid Hormone; PTH: Parathyroid
Hormone.
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